Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…
Hong Kong With Asia-Pacific poised to become a global force in cell and gene therapy, Xellera Therapeutics is positioning itself at the heart of this transformation. Led by CEO Camie Chan, the Hong Kong-based company is bridging critical infrastructure gaps by offering GMP-certified manufacturing, regulatory compliance aligned with global standards, and a…
Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…
Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…
Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…
Hong Kong In our field, success is not defined by short-term remission alone, but by long-term disease eradication. Our goal is always a cure, not prolonged management. After decades spent advancing paediatric oncology in Hong Kong, Professor Li Chi Kong has increased his focus toward the frontier of cell and gene therapies, spearheading…
Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…
China A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction of US biotech Illumina; Bio X Cell’s new Beijing distribution centre, and the European approval of Shanghai Henlius Biotech’s extensive-stage…
Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration. MediPharm Labs Enters Landmark Commercial…
Global With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick in investment, cell and gene therapies are set to continue making considerable headway in 2025. Yet their elevated price tag…
Switzerland iQone Healthcare has achieved impressive growth under the leadership of CEO Michele Genini, who has guided the company from launching a single biosimilar product in 2016 to building a diverse portfolio of seven. Now part of Celltrion and with a strategic focus on the Swiss market, iQone has become a…
Hong Kong Derek Chang introduces some of the key therapeutic advancements Novartis has been able to introduce in Hong Kong, including cell therapy and siRNA therapies, and its ongoing focus on targeted radioligand therapies, which benefit from the territory’s robust legislative framework. Chang also touches on the importance of Hong Kong’s “1+”…
See our Cookie Privacy Policy Here
